Selective inhibition of TNF-α-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib
2005
Gefitinib and Its Effects on Cancer Metastasis
Sample size: 5
publication
Evidence: moderate
Author Information
Author(s): Y Ueno, H Sakurai, M Matsuo, M K Choo, K Koizumi, I Saiki
Primary Institution: Toyama Medical and Pharmaceutical University
Hypothesis
Can gefitinib inhibit TNF-α-induced activation of signaling pathways and metastatic activities in hepatocellular carcinoma?
Conclusion
Gefitinib effectively inhibits TNF-α-induced activation of signaling pathways and metastatic properties in hepatocellular carcinoma.
Supporting Evidence
- Gefitinib inhibited EGF-induced activation of MAPK cascades.
- TNF-α mRNA was expressed in large quantities in the implanted tumor.
- Gefitinib blocked TNF-α-induced metastatic properties without affecting cell proliferation.
Takeaway
Gefitinib is a medicine that helps stop cancer cells from spreading by blocking certain signals in the body.
Methodology
The study used an intrahepatic metastasis model in mice and real-time RT-PCR to analyze gene expression.
Participant Demographics
Female 5-week-old specific pathogen-free B6C3F1 mice were used.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website